RDD Blog » 2009 » July

R&D Directions Insider

Archive for July, 2009

Mosquitoes deliver malaria immunity

Thursday, July 30th, 2009

Scientists may be on the right track in developing a vaccine against malaria using mosquitoes to deliver live malaria parasites through their bites. With reports showing that resistance is growing to artemisinin, the main drug used against malaria in the many areas where chloroquine is no longer effective, the need ...

Posted in clinical trials, infectious diseases, vaccines | No Comments »

These little piggies going to market?

Thursday, July 23rd, 2009

The future of diabetes treatment isn't going to the dogs, but it may be coming from the pigs. Living Cell Technologies (LCT) recently started implanting cells from newborn pigs into humans hoping to postpone blindness, premature coronary illness, and limb amputation resulting from poor blood circulation from type 1 diabetes. ...

Posted in animals, clinical trials, diabetes | No Comments »

CROs bear brunt as well, numbers show

Wednesday, July 22nd, 2009

Earnings season is upon us once again and when it comes to the drug industry, itâ€™s not just the big fish in big pharma that are under the microscope these days. The top publicly traded contract research organizations are also dealing with added scrutiny as they try to withstand the ...

Posted in CRO, Uncategorized | No Comments »

‘Milestone’ journey for anti-clotting agent

Thursday, July 16th, 2009

Since FDAâ€™s decision to green light long-awaited blood thinner entry Effient was announced late last week, there has been much talk on the financial front over just how big a threat the Eli Lilly and Daiichi Sankyo Co. drug, which must carry a black box warning, will pose to longtime ...

Posted in Uncategorized, clinical trials | No Comments »

Tiny delivery platform may have huge potential

Monday, July 13th, 2009

The application of nanotechnology in clinical development is a growing area of interest, and investors are apparently taking notice. Late last week, NanoBio Corp., a biopharmaceutical company specializing in nanotechnology, with development projects ranging from influenza vaccines to skin treatments to anti-infective products, landed an additional $10 million in funding, ...

Posted in Uncategorized | No Comments »

Roche deciphers cells with high content screening

Thursday, July 2nd, 2009

While other pharmaceutical companies may be taking a wait-and-see approach, Roche Nutley Research has been moving forward in using digital technology for drug discovery for the past ten years. To help find and validate promising drug candidates, the high content work group at Roche has been deciphering the microscopic language ...

Posted in drug discovery | No Comments »

©2012 UBM Canon